Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth
Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth Simply Wall Street
Covered in this story
Analyst targets on Amgen
- UBS: $415 → $470 by Oct 2027 · Buy via MarketBeat
- Morgan Stanley: $415 → $359 by Oct 2027 · Equal Weight via MarketBeat
- RBC Capital Markets: $406 → $430 by Oct 2027 via Pluang
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 5 Aug 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.